Insperity Stock Down 55% From Highs as Hedge Fund Buys $13 Million Stake — Is It A Turnaround Bet?

Stadium Capital Management initiated a new position in Insperity (NYSE:NSP), buying 263,715 shares worth about $13.0 million in Q3, representing 13.9% of the fund's $93.6 million reportable U.S. equity assets and making NSP its fourth-largest holding. Insperity reported TTM revenue of $6.8 billion and TTM net income of $17 million, but the most recent quarter showed revenue of $1.6 billion with a $20 million net loss and adjusted EBITDA of $10 million; shares trade at $35.37, down 55% year-over-year. Management highlighted cost controls and a multi-year UnitedHealthcare agreement that lowers the large-claim pooling level to $500,000 beginning in 2026, a development Stadium Capital appears to be betting will materially reduce claim exposure and support an operational recovery.

Analysis

Market structure: Stadium Capital’s $13m, 13.9% allocation to NSP signals concentrated value-capital rotating into distressed service providers; direct winners are Insperity equity holders and dividend-seeking allocators if margin recovery materializes, while short-duration vendors to SMBs and stop-loss insurers face renegotiated economics. Competitive dynamics shift in favor of entrenched full-service PEOs that secure favorable carrier contracts (NSP) — smaller rivals without large stop-loss arrangements could lose pricing power and clients. On supply/demand, a handful of active value managers can move a small-cap like NSP; expect episodic bid-support and elevated options vol as event risk (Q4 results, 2026 contract) approaches. Cross-asset: a visible dividend (7%) makes NSP act bond-like for income funds, while successful de-risking should compress implied equity risk premia and reduce put demand; no material FX/commodity impact expected.

Risk assessment: Tail risks include persistent healthcare inflation post-2026, material client churn if cost-savings are passed through, or a failed implementation with UnitedHealthcare that preserves large-claim volatility — each could collapse valuation >50%. Immediate (days): modest pop from 13F rebalancing; short-term (3–6 months): sensitivity to Q4 guidance and stop-loss pricing; long-term (12–24 months): realized margin improvement from the 2026 pooling change. Hidden dependencies: accuracy of stop-loss loss-runs, reinsurance capacity, and covenant/drain on cash if benefit mix changes. Key catalysts: Q4 earnings (next 30–60 days), 2026 contract implementation metrics, and management’s comms on client retention and cost controls.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in Insperity (NSP) at or below the current $35.4 level, tranche 25% now, 25% after Q4 beats, 50% toward $30; target 12–18 month upside to $50–56 and use a hard stop-loss at ~25% downside (~$26).
• Implement a Jan 2027 call spread (buy NSP Jan 2027 35C, sell Jan 2027 55C) sized to ~50% of your cash long exposure to capture 2026 UnitedHealthcare contract benefits while limiting premium outlay.
• Put on a pair trade: long NSP vs short TNET (TriNet) equal notional for 6–12 months — size so potential relative gain of 20–30% is portfolio-limited; exit if TNET outperforms by >15% or NSP misses two consecutive quarters of margin improvement.
• If unwilling to hold outright equity, buy Dec 2026 NSP 30 puts sized to 25–50% of notional as a protective hedge and reduce position if implied volatility spikes >40% or if management provides negative implementation metrics for the UnitedHealthcare contract.
• Monitor three triggers within the next 60 days before scaling: Q4 adjusted EBITDA margin improvement >200bp YoY, client retention rate above 95% in disclosure, and detailed UnitedHealthcare contract KPIs (claim pooling realized savings) — add to position if two of three are met, cut exposure if none are met.